Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | TNKS | O95271 | 2/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11883092 | 0.86 | KDM4E (0.75) | KDM4EALDH1A1CYP3A4HPGDCYP1A2 | |
| SCHEMBL9141500 | 0.86 | KDM4E (0.74) | KDM4EALDH1A1CYP3A4HPGDCYP1A2 | |
| SCHEMBL9140701 | 0.85 | KDM4E (0.74) | KDM4ECYP3A4CYP1A2MAPTTNKS | |
| SCHEMBL21629622 | 0.83 | ALDH1A1 (0.83) | KDM4EALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL8983924 | 0.82 | KDM4E (0.70) | KDM4EALDH1A1CYP3A4HPGDCYP1A2 | |
| SCHEMBL4053857 | 0.82 | KDM4E (0.80) | KDM4EALDH1A1CYP3A4HPGDCYP1A2 | |
| SCHEMBL10025659 | 0.81 | SIGMAR1 (0.76) | KDM4ECYP3A4MAPTTNKSCYP19A1 | |
| SCHEMBL4050048 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1CYP3A4HPGDCYP1A2 | |
| SCHEMBL10620445 | 0.80 | ALDH1A1 (0.75) | KDM4EALDH1A1CYP3A4HPGDCYP1A2 | |
| SCHEMBL9139841 | 0.80 | HPGD (0.80) | KDM4EALDH1A1CYP3A4HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-03-23 | — | — | US | claimed |
| EP-4000614-A1 | EFLOXATE FOR USE AS ANTIVIRAL AGENT | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2022-05-25 | — | — | EP | claimed |
| US-11324748-B2 | Vasodilators for treatment of heart failure | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-05-10 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| US-20200325543-A1 | DIAGNOSTIC METHOD | TOLREMO THERAPEUTICS AG (CH) | 2020-10-15 | — | — | US | claimed |
| EP-3714069-A1 | DIAGNOSTIC METHOD | Tolremo Therapeutics AG (CH) | 2020-09-30 | — | — | EP | claimed |
| CN-110128937-A | A kind of efficiency light mutagenesis color protective coating | 安徽五岳松纳米技术有限公司 | 2019-08-16 | — | — | CN | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-9982042-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| WO-2003026705-A1 | METHODS FOR STERILIZING BIOLOGICAL MATERIALS USING FLAVONOID/FLAVONOL STABILIZERS | CLEARANT, INC. (US) | 2003-04-03 | — | — | WO | claimed |
| US-20030059338-A1 | Methods for sterilizing biological materials using flavonoid/flavonol stabilizers | CLEARANT, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5399584-A | Preventing gastrointestinal damage caused by nonsteroidal antiinflammatory drugs | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093487-A1 | VASODILATORS FOR TREATMENT OF HEART FAILURE | VASP, TNNI3, EDNRB | KDM4E 4093/4885ALDH1A1 1929/4885CYP3A4 3813/4885 |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | KDM4E 4011/4885ALDH1A1 515/4885CYP3A4 867/4885 |
| US-11324748-B2 | Vasodilators for treatment of heart failure | VASP, TNNI3, EDNRB | KDM4E 4093/4885ALDH1A1 1929/4885CYP3A4 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.